Hikma Pharmaceuticals (HIK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,885.00p
   
  • Change Today:
    -6.00p
  • 52 Week High: 2,205.00p
  • 52 Week Low: 1,722.00p
  • Currency: UK Pounds
  • Shares Issued: 221.89m
  • Volume: 5,680
  • Market Cap: £4,182.54m
  • RiskGrade: 125

Hikma US unit launches anti-HIV tablet

By Frank Prenesti

Date: Tuesday 20 Mar 2018

LONDON (ShareCast) - (ShareCast News) - Generic drug maker Hikma Pharmaceuticals said its US subsidiary West-Ward had launched Ritonavir Tablets, the first AB-rated generic to Norvir tablets.
Citing an approval letter from the US Food and Drug Administration, Hikma said West-Ward was eligible for 180 days of generic drug exclusivity.

West-Ward's ritonavir is approved by FDA for use in combination with other antiretroviral agents for treatment of human immunodeficiency virus (HIV-1) infection.

West-Ward generics division president Brian Hoffmann said the company would be launching ritonavir with additional patient support and co-pay assistance "to ensure more people are able to access this life-saving medicine".

He added that West-Ward was launching an education and awareness campaign, including a website and direct communication.

According to medical information company IQVIA, US sales of Norvir were approximately $208.5m in 2017.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

HIK Market Data

Currency UK Pounds
Share Price 1,885.00p
Change Today -6.00p
% Change -0.32 %
52 Week High 2,205.00p
52 Week Low 1,722.00p
Volume 5,680
Shares Issued 221.89m
Market Cap £4,182.54m
RiskGrade 125

HIK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
48.07% below the market average48.07% below the market average48.07% below the market average48.07% below the market average48.07% below the market average
1.96% above the sector average1.96% above the sector average1.96% above the sector average1.96% above the sector average1.96% above the sector average
Price Trend
44.88% above the market average44.88% above the market average44.88% above the market average44.88% above the market average44.88% above the market average
69.81% above the sector average69.81% above the sector average69.81% above the sector average69.81% above the sector average69.81% above the sector average
Income
11.05% above the market average11.05% above the market average11.05% above the market average11.05% above the market average11.05% above the market average
71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average
Growth
31.5% below the market average31.5% below the market average31.5% below the market average31.5% below the market average31.5% below the market average
39.39% below the sector average39.39% below the sector average39.39% below the sector average39.39% below the sector average39.39% below the sector average

What The Brokers Say

Strong Buy 4
Buy 2
Neutral 4
Sell 1
Strong Sell 0
Total 11
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

HIK Dividends

  Latest Previous
  Final Interim
Ex-Div 21-Mar-24 10-Aug-23
Paid 03-May-24 15-Sep-23
Amount 47.00¢ 25.00¢

Trades for 01-Jul-2024

Time Volume / Share Price
08:29 25 @ 1,883.61p
08:29 226 @ 1,885.00p
08:29 148 @ 1,885.00p
08:29 148 @ 1,884.00p
08:25 39 @ 1,887.00p

HIK Key Personnel

CEO Riad Mishlawi

Top of Page